公开(公告)号：EP2240204A1

公开(公告)日：2010-10-20

申请号：EP09708994.0

申请日：2009-02-04

申请人： Medarex, Inc.

发明人： KORMAN, Alan ,  HALK, Edward, L. ,  WANG, Changyu ,  THUDIUM, Kent, B. ,  YANG, Lan ,  TOY, Kristopher

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2818 ,  A61K39/3955 ,  A61K2039/55516 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

摘要： The present invention provides isolated monoclonal antibodies that bind to CTLA-4 and that are capable of increasing the response of T cells to antigenic stimulation in vivo yet the antibodies do not substantially block the binding of CTLA-4 to B7 ligands (e.g., B7-1 and B7-2) in vitro. Thus, the antibodies of the invention demonstrate that is it possible to separate the immunostimulatory function of anti-CTLA-4 antibodies from their ability to block the binding of B7 ligands. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for increasing the response of T cells to antigenic stimulation using the antibodies of the invention, including methods for treating cancer using the antibodies of the invention.

公开(公告)号：EP2097447A2

公开(公告)日：2009-09-09

申请号：EP07871479.7

申请日：2007-11-15

申请人： Medarex, Inc.

发明人： KORMAN, Alan ,  SELBY, Mark ,  THUDIUM, Kent B. ,  HALK, Edward ,  SRINIVASAN, Mohan ,  PASSMORE, David B.

IPC分类号： C07K16/00 ,  A61K39/395

CPC分类号： C07K16/2818 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/92 ,  Y02A50/386 ,  Y02A50/403 ,  Y02A50/407 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/466 ,  Y02A50/472 ,  Y02A50/48

摘要： The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

公开(公告)号：EP2066351A2

公开(公告)日：2009-06-10

申请号：EP07867192.2

申请日：2007-10-01

申请人： Medarex, Inc.

发明人： KUHNE, Michelle ,  BRAMS, Peter ,  TANAMACHI, Dawn M. ,  KORMAN, Alan ,  CARDARELLI, Josephine M.

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2866 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/76

摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.